We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
A pair of prominent House Democrats has introduced legislation that would prevent
government officials from tampering with federal research and scientific policymaking.
Teva Pharmaceutical's U.S. generic pipeline currently
consists of 140 product applications, 26 of which it hopes to gain marketing
exclusivity for, the company said in its fourth-quarter earnings report.
Despite assurances that all medically necessary drugs must be made available
under the Medicare prescription drug benefit, the final guidelines for designing
the Rx formularies could still leave numerous drugs off the list, says a pharmaceutical
industry expert.
Conceding to the industry's demand, the government
hiked the abatement limit of excise duty on the retail price of drugs to 40
percent from 35 percent at present.
Pfizer has acquired San Diego-based Idun Pharmaceuticals, a company focused
on discovery and development of therapeutics in the area of liver disease, inflammation
and cancer.
Curacyte AG, a late stage drug discovery and development company has announced
its merger with IBFB PHARMA GmbH. IBFB PHARMA is a biopharmaceutical company
engaged in discovery and development of therapeutics to treat a variety of inflammatory
diseases.
Alpharma has entered into an agreement with Orchid Chemicals & Pharmaceuticals,
a Chennai-based global pharmaceutical company, whereby Orchid will develop,
manufacture and supply generic prescription products for exclusive sale by Alpharma.
Shire Pharmaceuticals Group Plc is confident Canadian regulators will reverse
a decision to suspend its top-selling hyperactivity drug, since the ban is not
justified, the company's chief executive has said.
Prolexys Pharmaceuticals, a biopharmaceutical company dedicated to the development
of novel cancer therapies, has signed an exclusive licensing agreement with
the Massachusetts Institute of Technology, acting as licensing agent for the
Whitehead Institute for Biomedical Research of Cambridge, Mass., and Columbia
University of New York City.